key: cord-0694733-8yl256eb
authors: Butler, Christopher C.
title: Response to Dal‐Ré and Holm's ethical concern regarding the UK PANORAMIC COVID‐19 trial by the PANORAMIC Investigators
date: 2022-03-10
journal: Br J Clin Pharmacol
DOI: 10.1111/bcp.15299
sha: 3802cf0f0a09a79b5efc6ccfd9dfa758523069e9
doc_id: 694733
cord_uid: 8yl256eb

nan

Molnupiravir has conditional marketing approval in the UK, recognizing that clinical data for full authorization are not yet available. PANORAMIC is a key contribution to generate these data.

For example, participants in the pivotal phase 3 trial (MOVe-OUT) were unvaccinated, exposed to different variants of SARs-CoV-2 from those in current circulation, and largely recruited in healthcare systems different from the UK. It is important to evaluate whether the treatment effect on which the conditional approval is based applies in a clinically relevant population in the UK. PANORAMIC thus represents a pragmatic means to assess molnupiravir and other potential treatments without denying participants access to treatments available through other approved routes.

Ethical concern regarding the UK PANORAMIC COVID-19 trial

Program, Grant/Award Number: NIHR135366.